ENTPD1 and primary cutaneous T-cell non-Hodgkin lymphoma: To better explore the potential use of adenosine pathway's antagonists for promoting malignant cells clearance in both blood and skin compartments, we further investigated CD39 expression in the cutaneous compartment of various CTCL subtypes.